Elanco Animal Health reported a 15% revenue increase in Q1 2026, driven by 10% organic growth and strong product performance across pet and farm animal segments. The company raised its full-year 2026 guidance, expecting revenue between $5.01 billion and $5.09 billion, adjusted EBITDA up 10%, and adjusted EPS growth of 13%. Key product innovations like Zenrelia and Credelio Quattro showed strong market gains, supporting improved financial targets and a better year-end net leverage ratio. Elanco's momentum and strategic investments position it for sustained growth in the animal health industry.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
